Performance status -2 - Symptomatic, 50 in bed - Page 2 of 3 Posts on Medivizor
Navigation Menu

Performance status -2 – Symptomatic, 50 in bed Posts on Medivizor

Searching for patients to test a combination of targeted therapies for chronic lymphocytic leukemia

Posted by on Mar 9, 2019 in Leukemia | 0 comments

In a nutshell This trial is examining the effectiveness of ibrutinib (Imbruvica) and obinutuzumab (Gazyva) with or without venetoclax (Venclexta) in the treatment of chronic lymphocytic leukemia (CLL). The main outcome to be measured will be survival without cancer growing or spreading. This trial is recruiting in various places around the...

Read More

Looking for patients with relapsed or unresponsive mantle cell lymphoma to test a new treatment

Posted by on Feb 28, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This phase 2 trial is evaluating the safety and effectiveness of a new targeted therapy for relapsed or unresponsive mantle cell lymphoma (MCL). The main outcome to be measured is the overall response rate to treatment. The details Ibrutinib (Imbruvica) is a commonly used therapy for patients with relapsed or refractory MCL. This...

Read More

Searching for patients with chronic lymphocytic leukemia to test zanubrutinib compared to ibrutinib

Posted by on Jan 27, 2019 in Leukemia | 0 comments

In a nutshell This trial is looking at the effectiveness of zanubrutinib compared to ibrutinib in the treatment of patients with unresponsive or relapsed chronic lymphocytic leukemia (CLL). The main outcome to be measured will be overall response rate. The study will be carried out in the United States.  The details Chronic...

Read More

Searching for patients to test venetoclax with azacitidine treatment for acute myeloid leukemia

Posted by on Jan 27, 2019 in Leukemia | 0 comments

In a nutshell This trial is comparing the safety and effectiveness of venetoclax (Venclexta) and azacitidine (Vidaza) with azacitidine alone in patients with acute myeloid leukemia (AML). The main outcome to be measured will be overall survival. Complete remission (no signs of cancer after treatment) will also be measured. The details Acute...

Read More

Ibrutinib in combination with bendamustine and rituximab improves quality of life factors in patients with severe impairment

Posted by on Feb 24, 2018 in Leukemia | 0 comments

In a nutshell This study examined how treatment with ibrutinib (Imbruvica), rituximab (Rituxan), and bendamustine (Treanda) impacts quality of life in chronic lymphocytic leukemia (CLL) patients. Factors such as fatigue, physical functioning, and well-being were all improved among those patients with the lowest scores before treatment. Some background...

Read More

Looking for participants with chronic myeloid leukemia to receive axitinib and bosutinib

Posted by on Feb 5, 2018 in Leukemia | 0 comments

In a nutshell This phase 1 and 2 trial aims to determine the effectiveness and optimal dose of Axitinib and Bosutinib in patients with chronic myeloid leukemia. The outcome to be measured is the response to treatment based on genetic analysis and blood cell count, and the side effects. The study is located in Houston, Texas, United States.  The...

Read More

Looking for patients with relapsed B-cell non-Hodgkin’s lymphoma to test the effectiveness of a copanlisib and rituximab combination treatment

Posted by on Sep 12, 2017 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This phase 3 clinical trial will evaluate the safety and effectiveness of a copanlisib (BAY 80-6946) and rituximab (Rituxan) combination in treating patients with relapsed indolent B-cell non-Hodgkin’s lymphoma (iNHL). The primary outcome will be measured by time to disease progression. The details Copanlisib is an inhibitor of...

Read More

Looking for patients with relapsed or refractory cutaneous lymphoma to test a novel immunotherapy

Posted by on Sep 11, 2017 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This phase 1/2 clinical trial will test the response to AFM13 in patients with relapsed or refractory cutaneous (on the skin) CD30 positive lymphomas. The primary outcome will be measured by immune system activity. This study will be conducted at the Center for Lymphoid Malignancies in New York, New York. The details AFM13 is an...

Read More

Looking for patients with untreated chronic lymphocytic leukemia to test an ibrutinib and fludarabine treatment

Posted by on Sep 11, 2017 in Leukemia | 0 comments

In a nutshell This phase 2 clinical trial will test the safety and effectiveness of an ibrutinib (Imbruvica) and fludarabine (Fludara) treatment in patients with previously untreated chronic lymphocytic leukemia (CLL). The primary outcome will be measured by the safety and effectiveness of the treatment. The details Ibrutinib is a drug that...

Read More

Looking for patients with relapsed or refractory acute myeloid leukemia to test either one or 2 immunotherapies with a chemotherapy

Posted by on Sep 11, 2017 in Leukemia | 0 comments

In a nutshell This phase 2 clinical trial will test the safety and tolerability of a nivolumab (Opdivo) and 5-azacytidine (Vidaza) combination with or without ipilimumab (Yervoy) in treating relapsed or refractory (unresponsive to treatment) acute myeloid leukemia (AML). The primary outcome will be measured by the maximum tolerated dose. This trial is...

Read More

Looking for patients with chronic myelogenous leukemia or Philadelphia chromosome positive acute lympholastic leukemia to test a BCR-ABL1 inhibitor

Posted by on Sep 11, 2017 in Leukemia | 0 comments

In a nutshell This phase 1 clinical trial will test the safety of ABL001 alone and with either nilotinib (Tasigna), imatinib (Gleevec), or dasatinib (Sprycel) in patients with chronic myelogenous leukemia (CML) or Philadelphia chromosome-positive acute lymphoblastic Leukemia (Ph+ALL). The primary outcome will be measured by side effects. The details...

Read More

Looking for patients with relapsed or refractory chronic lymphocytic leukemia, acute lymphoblastic leukemia, and non-Hodgkin’s lymphoma to test a CAR T-cell treatment

Posted by on Sep 3, 2017 in Leukemia | 0 comments

In a nutshell This phase 1/2 clinical trial will test the effectiveness of chimeric antigen receptor (CAR) T-cells in treating chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia (ALL), and non-Hodgkin’s lymphoma (NHL). The primary outcome will be measured by the response to treatment, overall survival, and the maximum tolerated...

Read More